Neurotechnology startup Mave Health has raised $2.1 million (around INR 18 crore) in a seed funding round led by Blume Ventures to scale its focus and stress regulation headset. The round also saw participation from Inuka Capital, Stanford Angels, the founders of Groww, Raymond Russell, Aureolis Ventures and Juhi Bhatnagar (Forj Capital), while existing investors such as All In Capital doubled down on their earlier backing. This follows Mave Health’s $750,000 pre-seed round completed in November 2023.
Founded in 2023 by Dhawal Jain, Jai Sharma and Aman Kumar, Mave Health is building a lightweight wearable headset designed to support everyday mental health and cognitive performance in just 20 minutes a day. The device uses transcranial direct current stimulation (tDCS), a form of non-invasive brain stimulation that has been researched for more than 25 years in over 10,000 published studies and is considered well-suited for at-home use owing to its safety profile. Mave has packaged this technology into a consumer-friendly, sub-100 gram headset paired with a mobile app.
Ahead of its public release last month, the company ran a beta programme with more than 500 users. Based on self-reported data after four weeks of use, 80 percent of users said their productivity improved by more than 60 percent, 75 percent reported stress reductions above 50 percent and average reported mood improvement was 77 percent. Users typically wear the device for 20 minutes daily while continuing routine activities, and most report noticeable changes within 15–20 days, with benefits compounding over time.
“The brain is the most complex system we rely on every day, and modern life is constantly overloading it. We expect it to perform at peak levels without giving it the support it needs,” said Dhawal Jain, Co-founder and CEO, Mave Health. “Instead of chasing short-term boosts that come with long-term costs, we believe in strengthening the underlying systems that drive focus, mood and stress regulation. Our goal is to make brain health tools as accessible and routine as fitness trackers.”
The newly raised capital will be used to launch Mave’s headset in the United States and India and to expand manufacturing capacity. The company has already seen strong early demand, with three limited batches selling out within 36 hours and its launch video crossing one million impressions across social media platforms. The product has also caught the attention of global technology leaders and athletes, including UFC fighter Max Griffin.
“Neurotechnology has the potential to enhance human experience. New-age microelectronic devices like Mave are making it accessible to consumers by moving beyond the clinic, in a way that merges seamlessly with our lifestyle,” said Arpit Agarwal, Investment Partner at Blume Ventures. “This could shift the way individuals manage their mood, stress and overall well-being. We are excited to partner with the team, which is passionate about building a category-defining consumer device company from India for the global market.”
The Mave headset delivers low-intensity electrical stimulation targeted at the prefrontal cortex, a brain region linked to attention, emotional regulation and stress response. The companion app lets users log sessions, personalise protocols and track their progress without collecting any brain data. The device offers up to a month of battery life on a single charge with regular use.
Mave’s headset is currently available for pre-order in the US and India, with shipping scheduled to begin in April 2026.
